AU2019269131B2 - Antibodies against LIF and dosage forms thereof - Google Patents

Antibodies against LIF and dosage forms thereof Download PDF

Info

Publication number
AU2019269131B2
AU2019269131B2 AU2019269131A AU2019269131A AU2019269131B2 AU 2019269131 B2 AU2019269131 B2 AU 2019269131B2 AU 2019269131 A AU2019269131 A AU 2019269131A AU 2019269131 A AU2019269131 A AU 2019269131A AU 2019269131 B2 AU2019269131 B2 AU 2019269131B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
set forth
lif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019269131A
Other languages
English (en)
Other versions
AU2019269131A1 (en
Inventor
Judit Anido Folgueira
Joan Seoane Suarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institució Catalana de Recerca i Estudis Avançats
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Original Assignee
Institució Catalana de Recerca i Estudis Avançats
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institució Catalana de Recerca i Estudis Avançats, Fundació Privada Institut d'Investigació Oncològica Vall-Hebron, MedImmune Ltd filed Critical Institució Catalana de Recerca i Estudis Avançats
Publication of AU2019269131A1 publication Critical patent/AU2019269131A1/en
Application granted granted Critical
Publication of AU2019269131B2 publication Critical patent/AU2019269131B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019269131A 2018-05-14 2019-05-13 Antibodies against LIF and dosage forms thereof Ceased AU2019269131B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18382327.7 2018-05-14
EP18382327 2018-05-14
EP18382359 2018-05-25
EP18382359.0 2018-05-25
EP19382208.7 2019-03-26
EP19382208 2019-03-26
EP19382331.7 2019-05-03
EP19382331 2019-05-03
PCT/IB2019/000541 WO2019220204A2 (en) 2018-05-14 2019-05-13 Antibodies against lif and dosage forms thereof

Publications (2)

Publication Number Publication Date
AU2019269131A1 AU2019269131A1 (en) 2021-01-07
AU2019269131B2 true AU2019269131B2 (en) 2024-02-22

Family

ID=67902550

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019269131A Ceased AU2019269131B2 (en) 2018-05-14 2019-05-13 Antibodies against LIF and dosage forms thereof

Country Status (10)

Country Link
US (1) US20220064279A1 (enExample)
EP (1) EP3794031A2 (enExample)
JP (2) JP7536654B2 (enExample)
KR (1) KR20210008514A (enExample)
CN (1) CN112638941A (enExample)
AU (1) AU2019269131B2 (enExample)
CA (1) CA3099406A1 (enExample)
MA (1) MA52021A (enExample)
SG (1) SG11202011170YA (enExample)
WO (1) WO2019220204A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7379390B2 (ja) * 2018-06-18 2023-11-14 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021110873A1 (en) * 2019-12-04 2021-06-10 Medimmune Limited Antibodies against lif and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089614A1 (en) * 2015-11-27 2017-06-01 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2019197903A1 (en) * 2018-04-12 2019-10-17 Mosaic Biomedicals Slu Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
AU2015314980A1 (en) * 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
CA2963712A1 (en) * 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089614A1 (en) * 2015-11-27 2017-06-01 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2019197903A1 (en) * 2018-04-12 2019-10-17 Mosaic Biomedicals Slu Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hyman, D. et al., 'Abstract - A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors', (2018-05-01), XP002795313, Database accession no. EMB-625977303. *
Magram, J. et al., (2017-10-29), XP002785420, Retrieved from the Internet http://northernbiologics.com/wp-content/uploads/2017/10/AACR-Molecular-targets-2017-poster.pdf *
Sinclair, A. et al., 'Abstract 1751' , (2018-04-18), XP002795312, Database accession no. EMB-623505072. *

Also Published As

Publication number Publication date
AU2019269131A1 (en) 2021-01-07
US20220064279A1 (en) 2022-03-03
JP2021523906A (ja) 2021-09-09
SG11202011170YA (en) 2020-12-30
WO2019220204A3 (en) 2019-12-26
JP2024160301A (ja) 2024-11-13
MA52021A (fr) 2021-03-24
WO2019220204A2 (en) 2019-11-21
CA3099406A1 (en) 2019-11-21
KR20210008514A (ko) 2021-01-22
CN112638941A (zh) 2021-04-09
JP7536654B2 (ja) 2024-08-20
EP3794031A2 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
US10206999B2 (en) Antibodies against LIF and uses thereof
US20230042095A1 (en) Antibodies against lif and uses thereof
JP2024160301A (ja) Ｌｉｆに対する抗体及びそれらの投与形態
AU2019251289B2 (en) Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
EP3806960A1 (en) Methods of quantifying lif and uses thereof
AU2019291307B2 (en) Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
HK40107591A (en) Antibodies against lif and uses thereof
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
HK40042216A (en) Antibodies against lif and dosage forms thereof
HK40016422A (en) Antibodies against lif and uses thereof
HK40016422B (en) Antibodies against lif and uses thereof
EA051297B1 (ru) Антитела к lif и их применения
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo
EA045781B1 (ru) Антитела к lif и их применения
TW202535949A (zh) 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired